Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

Sanofi and Regeneron were recruiting patients as of June 19 for a Phase III trial (NCT 02134028) designed to assess the long-term safety and tolerability of dupilumab in patients with asthma who ...

second confirmatory trial will commence in third quarter of 2020 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced updates related to the Dupixent ® (dupilumab) collaboration programs with ...

Sanofi and Regeneron are studying dupilumab in ... For more information on dupilumab clinical trials please visit www.clinicaltrials.gov. Tell your healthcare provider about all the medicines ...

Sanofi and Regeneron have followed up with data on other measurements. The trial linked both dupilumab regimens—which gave the experimental drug with topical corticosteroids—to statistically ...

Sanofi and Regeneron have put their experimental antibody dupilumab into a Phase III trial assessing its potential in uncontrolled persistent asthma, which the firms hope will serve as one of the ...

Sanofi and Regeneron are putting their investigational monoclonal antibody dupilumab into late-stage trials for moderate to severe asthma on the back of positive Phase IIb data. Sanofi and Regeneron ...

Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab. (Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743 ...

Regeneron ($REGN) and its close partner Sanofi ($SNY) have cleared the final mid-stage hurdle for dupilumab in asthma patients, with several doses hitting the trial ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

PARIS-- French drug giant Sanofi (SAN.FR) and U.S. partner Regeneron Pharmaceuticals REGN said a one-year phase three trial study showed a treatment combining their drug dupilumab with topical ...